Urovant Sciences Ltd. Stock

UROV

BMG9381B1081

Biotechnology & Medical Research

Latest news: Urovant Sciences Ltd.

22-07-05	Urovant Sciences and Pierre Fabre Médicament Enters into Exclusive License Agreement	CI
22-05-15	Urovant Sciences Ltd. Presents New Data from EMPOWUR Study, Advancing Knowledge of the Treatment of Overactive Bladder at the 2022 American Urological Association Meeting	CI
22-05-13	Urovant Sciences Presents Interim Data from Phase 2a Study of Investigational Novel Gene Therapy, URO-902, Supporting Safety, Tolerability, and Efficacy Endpoints	CI
22-04-19	Urovant Sciences Announces the Publication of A New, Post-Hoc Analysis of Data from the Phase 3 EMPOWUR Trial of GEMTESA 75 Mg in the International Journal of Clinical Practice	CI
22-04-04	Urovant Sciences Announces Management Changes	CI
21-10-26	Urovant Sciences Ltd. Announces Executive Changes	CI
21-08-20	Urovant Sciences Names Betzy Estrada as Executive VP and Chief Human Resources Officer	CI
21-08-18	Urovant Sciences to Present Key Data for GEMTESA® 75 Mg At the 2021 Annual Meeting of the American Urological Association	CI
21-03-31	Urovant Sciences Ltd.(NasdaqGS:UROV) dropped from S&P TMI Index	CI
21-03-29	Urovant Sciences Ltd. Announces Board Changes	CI
21-03-29	Urovant Sciences Ltd.(NasdaqGS:UROV) dropped from NASDAQ Composite Index	CI
21-03-28	Sumitovant Biopharma Ltd. completed the acquisition of the remaining 27.6% stake in Urovant Sciences Ltd..	CI
21-03-23	Urovant Sciences Ltd. - Shareholder/Analyst Call

More news

Analysts' recommendations: Urovant Sciences Ltd.

20-11-16	Urovant Sciences : HC Wainwright Downgrades Urovant Sciences to Neutral From Buy; Price Target is $16.25	MT
20-11-16	Urovant Sciences : JPMorgan Downgrades Urovant Sciences to Neutral From Overweight; Price Target is $16	MT
20-11-13	Urovant Sciences : Jefferies Downgrades Urovant Sciences to Hold From Buy; Lowers PT to $16.25 From $18	MT

More recommendations

Press Releases: Urovant Sciences Ltd.

22-04-13	Urovant Sciences to Present Interim Data from Phase 2a Study of Potential Novel Gene Therapy, URO-902, and New Analyses of Data from Phase 3 EMPOWUR Extension Trial of GEMTESA® (vibegron) 75 mg at 2022 American Urological Association Annual Meeting	BU
22-03-07	Urovant Sciences Announces Positive Topline Results of Phase 2a Trial of its Potential Novel Gene Therapy, URO-902	BU
21-12-20	Urovant Sciences Announces Publication in Advances in Therapy of Analyses of Patient-Perceived Meaningfulness of Improvement in Symptom Reduction for Overactive Bladder Patients Treated with GEMTESA® (vibegron) 75 mg	BU
21-11-08	Urovant Sciences Announces Publication in Blood Pressure Monitoring of Positive Ambulatory Blood Pressure Study Results for GEMTESA® (vibegron) 75 mg in Overactive Bladder Patients	BU
21-03-29	UROVANT SCIENCES LTD. : Completion of Acquisition or Disposition of Assets, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Material Modification to Rights of Security Holders, Change in Directors or Principal Officers, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Other Events, Financial Statements and Exhibits (form 8-K)	AQ

More press releases

Managers and Directors: Urovant Sciences Ltd.

Manager	Title	Age	Since
James Robinson CEO	Chief Executive Officer	56	2020-03-22
Ajay Bansal DFI	Director of Finance/CFO	64	2019-10-27
Cornelia Haag-Molkenteller CTO	Chief Tech/Sci/R&D Officer	68	2018-03-31

Director	Title	Age	Since
Sef P. Kurstjens BRD	Director/Board Member	62	2018-06-30
James Robinson BRD	Director/Board Member	56	2019-02-28
Shigeyuki Nishinaka BRD	Director/Board Member	61	2019-12-26

More insiders

Urovant Sciences Ltd. is a biopharmaceutical company. The Company is focused on developing and commercializing therapies for a range of urologic conditions. The Company's lead product, GEMTESA (vibegron), is an oral, once-daily (75 mg) small molecule beta-3 agonist for the treatment of adult patients with overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency, and urinary frequency. GEMTESA is also being evaluated for the treatment of OAB in men with benign prostatic hyperplasia. The Company's second product candidate, URO-902, is a gene therapy being developed for patients with OAB who have failed oral pharmacologic therapy.

Employees

Sector

Biotechnology & Medical Research

More about the company

Date	Insider	Type	Main position	Quantity	% Market Cap.
3/29/21	Sef P. Kurstjens	Issuer sale	Director	111,480	0.3405%
3/29/21	Pierre Legault	Issuer sale	Director	111,480	0.3405%
3/29/21	Christine Ocampo	Issuer sale	Controller/Auditor	286,031	0.8736%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
UROVANT SCIENCES LTD.	+0.06%	+0.06%	-	-	373M
Average	+0.06%
Weighted average by Cap.	+0.06%

Urovant Sciences Ltd. Stock

Stocks

UROV

BMG9381B1081

Biotechnology & Medical Research

Latest news: Urovant Sciences Ltd.

Analysts' recommendations: Urovant Sciences Ltd.

Press Releases: Urovant Sciences Ltd.

Quotes and Performance

Managers and Directors: Urovant Sciences Ltd.

Latest insider transactions

Bio Therapeutic Drugs

Company Profile